| Literature DB >> 24522248 |
Lisa Pleyer1, Ulrich Germing2, Wolfgang R Sperr3, Werner Linkesch4, Sonja Burgstaller5, Reinhard Stauder6, Michael Girschikofsky7, Martin Schreder8, Michael Pfeilstocker9, Alois Lang10, Thamer Sliwa11, Dietmar Geissler12, Konstantin Schlick1, Gudrun Placher-Sorko1, Georg Theiler4, Josef Thaler5, Martina Mitrovic6, Daniel Neureiter13, Peter Valent3, Richard Greil14.
Abstract
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.Entities:
Keywords: Austrian Azacitidine Registry; Azacitidine; CMML; Chronic myelomonocytic leukemia; Matched-pair analysis
Mesh：
Substances：
Year: 2014 PMID： 24522248 DOI： 10.1016/j.leukres.2014.01.006
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156